No validated biomarkers beyond PD-L1 currently guide immune checkpoint inhibition (ICI) in advanced triple-negative breast cancer (TNBC), and how tumors remodel their microenvironment in response to ICI remains incompletely understood. We perform a temporal analysis of patients with advanced TNBC treated with chemo-imm...
N. Van Renne, E. Agostinetto, Andrea Joaquín-García et al.· Cell Reports Medicine· 0 citations
This Primer provides a comprehensive guide to the experimental IMC workflow, covering antibody conjugation and panel design, sample preparation, data acquisition and quality control, and detail the computational analysis pipeline, including image preprocessing, segmentation, feature extraction, and both single-cell and...
Lasse Meyer, S. Haefliger, D. Schulz et al.· Nature Reviews Methods Prime...· 0 citations
FACTMx couples latent patient factors with subobservation clustering and per-patient component proportions, enabling direct interpretation and downstream association analyses, and supports joint structured-simple modelling for interpretable multimodal patient stratification.
Kazimierz Oksza-Orzechowski, Małgorzata Łazȩcka, Ł. Koperski et al.· bioRxiv· 0 citations
It is demonstrated that integrated multimodal tumor profiling can inform personalized maintenance treatment decisions and that chemotherapy reshapes tumor cell diversity.
Francis Jacob, R. Wegmann, Joanna Ficek-Pascual et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
